Wednesday, July 8, 2026

Drug profile · INN

lypressin

lypressin (DIAPID) is a vasopressin receptor agonist. Route of administration: nasal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — lypressin
US status
approved
Class
Route
NASAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

lypressin (DIAPID) is a vasopressin receptor agonist. Route of administration: nasal. Current US regulatory status: approved.

Key facts

INN lypressin
Brand DIAPID
Mechanism Vasopressin receptor agonist
Target Vasopressin receptor
Route NASAL
Formulation SOLUTION

Mechanism of action

Vasopressin receptor agonist

Primary target: Vasopressin receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. desmopressin acetate Vasopressin receptor agonist
  2. vasopressin Vasopressin receptor agonist

Frequently asked questions

What is lypressin?

lypressin (DIAPID) is a vasopressin receptor agonist. Route of administration: nasal. Current US regulatory status: approved.

What is the brand name for lypressin?

DIAPID is a marketed brand name for lypressin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lypressin?

lypressin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.